IP Library Granted Patent US 8,546,342
Granted Patent B2
US 8,546,342 · App. 13/409,902 · Granted Oct 1, 2013

Composition for treating mental health disorders

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,546,342
App. No.
13/409,902
Granted
Oct 1, 2013
Kind
B2
Abstract

A composition of three compounds each selected from a selective re-uptake inhibitor of serotonin, a monoamine oxidase inhibitor, and a phosphodiesterase inhibitor, such that all three compounds are different and are naturally occurring.

Claims (24)

1. A method for treating depression, the method comprising administering to a subject in need thereof an effective amount of a composition that includes three different compounds selected from the group consisting of glabridin, resveratrol, quercetin, and isoquercetin.

2. The method of claim 1 , wherein the depression is a major depressive disorder, an atypical depression, a bipolar disorder, or a dysthymic disorder.

3. The method of claim 1 , wherein the composition further includes vitamin C or vitamin B3.

4. The method of claim 1 , wherein the composition includes glabridin, resveratrol, and isoquercetin, and the effective amount of the composition to be administered to the subject contains a daily dosage of 20-3000 mg glabridin, 50-3000 mg resveratrol, and 50-4000 mg isoquercetin.

5. The method of claim 4 , wherein the daily dosage of glabridin is 40-2000 mg, the daily dosage of resveratrol is 100-2000 mg, and the daily dosage of isoquercetin is 100-3000 mg.

6. The method of claim 4 , wherein the composition further includes vitamin C and vitamin B3 at a daily dosage of 20-2000 mg and 1-200 mg, respectively.

7. The method of claim 1 , wherein the composition includes glabridin, resveratrol, and quercetin, and the effective amount of the composition to be administered to the subject contains a daily dosage of 20-3000 mg glabridin, 50-3000 mg resveratrol, and 50-4000 mg quercetin.

8. The method of claim 7 , wherein the daily dosage of glabridin is 40-2000 mg, the daily dosage of resveratrol is 100-2000 mg, and the daily dosage of quercetin is 100-3000 mg.

9. The method of claim 7 , wherein the composition further includes vitamin C and vitamin B3 at a daily dosage of 20-2000 mg and 1-200 mg, respectively.

10. The method of claim 1 , wherein the composition includes isoquercetin, resveratrol, and quercetin, and the effective amount of the composition to be administered to the subject contains a daily dosage of 20-3000 mg isoquercetin, 50-3000 mg resveratrol, and 50-4000 mg quercetin.

11. The method of claim 10 , wherein the daily dosage of isoquercetin is 40-2000 mg, the daily dosage of resveratrol is 100-2000 mg, and the daily dosage of quercetin is 100-3000 mg.

12. The method of claim 10 , wherein the composition further includes vitamin C and vitamin B3 at a daily dosage of 20-2000 mg and 1-200 mg, respectively.

13. A method for treating anxiety, the method comprising administering to a subject in need thereof an effective amount of a composition that includes three different compounds selected from the group consisting of glabridin, resveratrol, quercetin, and isoquercetin.

14. The method of claim 13 , wherein the anxiety is a panic disorder, a phobia, an obsessive-compulsive disorder, a posttraumatic stress disorder, or a generalized anxiety disorder.

15. The method of claim 13 , wherein the composition further includes vitamin C or vitamin B3.

16. The method of claim 13 , wherein the composition includes glabridin, resveratrol, and isoquercetin, and the effective amount of the composition to be administered to the subject contains a daily dosage of 20-3000 mg glabridin, 50-3000 mg resveratrol, and 50-4000 mg isoquercetin.

17. The method of claim 16 , wherein the daily dosage of glabridin is 40-2000 mg, the daily dosage of resveratrol is 100-2000 mg, and the daily dosage of isoquercetin is 100-3000 mg.

18. The method of claim 13 , wherein the composition further includes vitamin C and vitamin B3 at a daily dosage of 20-2000 mg and 1-200 mg, respectively.

19. The method of claim 13 , wherein the composition includes glabridin, resveratrol, and quercetin, and the effective amount of the composition to be administered to the subject contains a daily dosage of 20-3000 mg glabridin, 50-3000 mg resveratrol, and 50-4000 mg quercetin.

20. The method of claim 19 , wherein the daily dosage of glabridin is 40-2000 mg, the daily dosage of resveratrol is 100-2000 mg, and the daily dosage of quercetin is 100-3000 mg.

21. The method of claim 19 , wherein the composition further includes vitamin C and vitamin B3 at a daily dosage of 20-2000 mg and 1-200 mg, respectively.

22. The method of claim 13 , wherein the composition includes isoquercetin, resveratrol, and quercetin, and the effective amount of the composition to be administered to the subject contains a daily dosage of 20-3000 mg isoquercetin, 50-3000 mg resveratrol, and 50-4000 mg quercetin.

23. The method of claim 22 , wherein the daily dosage of isoquercetin is 40-2000 mg, the daily dosage of resveratrol is 100-2000 mg, and the daily dosage of quercetin is 100-3000 mg.

24. The method of claim 22 , wherein the composition further includes vitamin C and vitamin B3 at a daily dosage of 20-2000 mg and 1-200 mg, respectively.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2020
From: QUERCEGEN PHARMA A.G.
To: LINES, THOMAS CHRISTIAN
Reel/Frame 052151/0234 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2020
From: LINES, THOMAS CHRISTIAN
To: QUERCIS PHARMA A.G.
Reel/Frame 052153/0756 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 13, 2020
From: LINES, THOMAS; QUERCEGEN PHARMA LLC; QUERCEGEN PHARMA LLP; QUERCEGEN TECHNOLOGIES; QUERCEGEN PHARMACEUTICALS, LLC; QUERCEGEN HOLDINGS, LLC; NEW SUN NUTRITION, LLC; THE FRS COMPANY
To: QUERCEGEN PHARMA, AG.
Reel/Frame 052110/0530 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 2012
From: LINES, THOMAS CHRISTIAN
To: SIRTUIN TECHNOLOGIES, INC.
Reel/Frame 028242/0018 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 2012
From: SIRTUIN TECHNOLOGIES, INC.
To: QUERCEGEN PHARMACEUTICALS LLC
Reel/Frame 028242/0055 →